Clinical Outcomes, Drug Toxicity, and Emergence of Ceftazidime-Avibactam Resistance Among Patients Treated for Carbapenem-Resistant Enterobacteriaceae Infections.
Thirty-seven carbapenem-resistant Enterobacteriaceae (CRE)-infected patients were treated with ceftazidime-avibactam. Clinical success and survival rates at 30 days were 59% (22/37) and 76% (28/37), respectively. In 23% (5/22) of clinical successes, CRE infections recurred within 90 days. Microbiologic failure rate was 27% (10/37). Ceftazidime-avibactam resistance was detected in 30% (3/10) of microbiologic failures.
Department of Medicine.|Antibiotic Management Program.|XDR Pathogen Laboratory, University of Pittsburgh Medical Center.
Ryan K
RK
Shields
Department of Medicine.|Department of Pharmacy and Therapeutics, University of Pittsburgh.|Antibiotic Management Program.
Brian A
BA
Potoski
Department of Medicine.
Ghady
G
Haidar
XDR Pathogen Laboratory, University of Pittsburgh Medical Center.
Binghua
B
Hao
Department of Medicine.
Yohei
Y
Doi
Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark.
Liang
L
Chen
Department of Medicine.
Ellen G
EG
Press
Public Health Research Institute Tuberculosis Center, New Jersey Medical School, Rutgers University, Newark.
Barry N
BN
Kreiswirth
Department of Medicine.|XDR Pathogen Laboratory, University of Pittsburgh Medical Center.|VA Pittsburgh Healthcare System, Pennsylvania.
Cornelius J
CJ
Clancy
Department of Medicine.|Antibiotic Management Program.|XDR Pathogen Laboratory, University of Pittsburgh Medical Center.
M Hong
MH
Nguyen
D000328:Adult; D000368:Aged; D053961:Azabicyclo Compounds / Q000009:adverse effects / Q000627:therapeutic use*; D000073182:Carbapenem-Resistant Enterobacteriaceae; D002442:Ceftazidime / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D024881:Drug Resistance, Bacterial; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D016896:Treatment Outcome; D065093:beta-Lactamase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D053961:Azabicyclo Compounds; D004338:Drug Combinations; C000595613:avibactam, ceftazidime drug combination; D065093:beta-Lactamase Inhibitors; D002442:Ceftazidime
Klebsiella pneumoniae carbapenemase; carbapenem-resistant Enterobacteriaceae; ceftazidime-avibactam resistance